Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NVO with free AI briefings, catalyst countdowns, and dilution alerts.

NVO · Novo Nordisk A/S

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$46.4B Cash on Hand
CF+ Cash Runway
1.2% Short Interest
$45.74 Analyst Target (12)
Follow NVO by email Get an email when NVO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NVO, unsubscribe in one click. Privacy

📣 What NVO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Oral Semaglutide
FDA approved Dec 2017 · Ozempic
Liver Transplant; Complications Phase 4 · NCT05195944 Active not recruiting
Somapacitan
FDA approved Aug 2020 · Sogroya
Growth Hormone Deficiency in Children Phase 3 · NCT03811535 Completed
Somatropin
FDA approved Jun 2000 · Norditropin Flexpro
Growth Hormone Deficiency in Children Phase 3 · NCT03811535 Completed
Concizumab
FDA approved Dec 2024 · Alhemo
Congenital Haemophilia N/A · NCT04921956 No longer available
NNC6019-0001 Transthyretin Amyloid Cardiomyopathy (ATTR CM) Phase 3 · NCT07207811 Recruiting
Zenagamtide Diabetes Mellitus, Type 2 Phase 3 · NCT07931495 Not yet recruiting
SOMATROPINE* : Norditropine® simplexx® Anorexia Nervosa Phase 2/3 · NCT01626833 Completed
Eptacog Alfa Intracerebral Hemorrhage Phase 3 · NCT07227246 Recruiting
NNC0487-0111 Diabetes Mellitus Phase 3 · NCT07533175 Active not recruiting
Cagrilintide Overweight Phase 3 · NCT07220759 Active not recruiting
Cagrisema Hypertension Phase 3 · NCT07919405 Not yet recruiting
Dasiglucagon Diabetes Mellitus, Type 1 Phase 3 · NCT06588504 Completed
Denecimig Haemophilia A Phase 3 · NCT07830732 Recruiting
KBP-5074 Capsule Chronic Kidney Diseases Phase 3 · NCT04968184 Terminated
NNC0662-3168 (Test product-A) Overweight Phase 1/2 · NCT07940803 Not yet recruiting
Active Comparator: 6.0mg GRI-0621 Overweight Phase 1/2 · NCT07940803 Not yet recruiting

Also used in these trials (approved or third-party drugs, not NVO's own candidates): Sitagliptin, Tirzepatide, Glucagon, Liraglutide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NVO holds $46.4B in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NVO files for a raise →

Get the full NVO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NVO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.